{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:57:29Z","timestamp":1786121849992,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:46:34Z","timestamp":1780001194000},"page":"547-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium\u2013Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents"],"prefix":"10.1016","volume":"55","author":[{"given":"Husam","family":"Ghanim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambasiva Rao","family":"Srungavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Dandona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ecl.2026.04.009_bib1","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.009_bib2","doi-asserted-by":"crossref","first-page":"e2526353","DOI":"10.1001\/jamanetworkopen.2025.26353","article-title":"Trends and disparities in technology use and glycemic control in type 1 diabetes","volume":"8","author":"Fang","year":"2025","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib3","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/dom.16300","article-title":"Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States","volume":"27","author":"Xu","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.009_bib4","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/oby.70033","article-title":"Understanding the increasing prevalence of obesity in patients with type 1 diabetes: strategies for improving clinical care","volume":"33","author":"Ruddiman","year":"2025","journal-title":"Obesity"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.009_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-017-0918-8","article-title":"Weight management in patients with type 1 diabetes and obesity","volume":"17","author":"Mottalib","year":"2017","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ecl.2026.04.009_bib6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1007\/s00125-013-2904-2","article-title":"Insulin resistance in type 1 diabetes: what is \u201cdouble diabetes\u201d and what are the risks?","author":"Cleland","year":"2013","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.009_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","article-title":"Obesity in people living with type 1 diabetes","volume":"9","author":"Van der Schueren","year":"2021","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"14","key":"10.1016\/j.ecl.2026.04.009_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2024.06.024","article-title":"Cardiorenal outcomes in middle-aged and older adults with type 1 and type 2 diabetes","volume":"84","author":"Ostrominski","year":"2024","journal-title":"JACC"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country Nationwide observational study","volume":"44","author":"Krist\u00f3fi","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s13300-023-01399-0","article-title":"Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: results from NHANES 2009\u20132020","volume":"14","author":"Hankosky","year":"2023","journal-title":"Diabetes Therapy"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.009_bib12","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahren","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.009_bib13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.009_bib14","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.009_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.009_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/19322968231223991","article-title":"Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study","volume":"19","author":"Akturk","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"50","key":"10.1016\/j.ecl.2026.04.009_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046446","article-title":"Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: a systematic review and meta-analysis","volume":"104","author":"Dutta","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.009_bib18","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/dom.14532","article-title":"Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials","volume":"23","author":"Dejgaard","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.009_bib19","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20132026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.009_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocrine reviews"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.009_bib21","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1111\/dom.70506","article-title":"Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: systematic review and meta-analysis","volume":"28","author":"Abdel-Rahman","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ecl.2026.04.009_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1506652","article-title":"Safety and efficacy of adjuvant Sotagliflozin therapy in patients with T1D - an update and systematic review and meta-analysis","volume":"16","author":"Lei","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.009_bib23","article-title":"Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review","volume":"19","year":"2018","journal-title":"Reviews in cardiovascular medicine"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.009_bib25","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.009_bib26","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.009_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/17512433.2023.2274988","article-title":"The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?","volume":"16","author":"Popovic","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 7","key":"10.1016\/j.ecl.2026.04.009_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/dom.15921","article-title":"Continuous ketone monitoring: exciting implications for clinical practice","volume":"26 Suppl 7","author":"Kong","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib29","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41591-026-04274-0","article-title":"Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes","volume":"32","author":"Xu","year":"2026","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.ecl.2026.04.009_bib30","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"JACC"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.009_bib31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.009_bib32","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.009_bib33","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2337\/dc18-2460","article-title":"Combination therapy with canagliflozin plus liraglutide exerts additive effect on weight loss, but not on HbA(1c), in patients with type 2 diabetes","volume":"43","author":"Ali","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib36","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"Singh","year":"2022","journal-title":"World J Cardiol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.009_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/1573399814666180813124645","article-title":"Hormonal, metabolic and hemodynamic adaptations to glycosuria in type 2 diabetes patients treated with sodium-glucose Co-transporter inhibitors","volume":"15","author":"Cersosimo","year":"2019","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.009_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.009_bib40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/oby.23677","article-title":"Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes","volume":"31","author":"Al-Ozairi","year":"2023","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10.1016\/j.ecl.2026.04.009_bib41","article-title":"Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg\/m(2), and chronic kidney disease - a randomised, controlled pilot study","volume":"231","author":"Al","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.009_bib42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.009_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.009_bib44","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring, Md)"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.009_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/dom.16078","article-title":"One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA","volume":"27","author":"Zhang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.009_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101594","article-title":"Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nature medicine"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.009_bib48","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/dom.12944","article-title":"Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib49","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1111\/dom.70640","article-title":"Cardio-kidney-metabolic therapy use among adults with type 1 diabetes and chronic kidney disease","volume":"28","author":"Caramori","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.009_bib50","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/13543784.2022.2159806","article-title":"Recent developments in adjunct therapies for type 1 diabetes","volume":"31","author":"Timmons","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.009_bib51","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2337\/dc20-2816","article-title":"Presence and determinants of cardiovascular disease and mortality in individuals with type 1 diabetes of long duration: the FinnDiane 50 Years of diabetes study","volume":"44","author":"Harjutsalo","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.009_bib52","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.009_bib53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2337\/dc18-1446","article-title":"BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox","volume":"42","author":"Edqvist","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib54","first-page":"299","article-title":"Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon","volume":"22","author":"Beylot","year":"1996","journal-title":"Diabetes & metabolism"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.009_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00000441-200605000-00002","article-title":"Overview of the diagnosis and management of diabetic ketoacidosis","volume":"331","author":"Eledrisi","year":"2006","journal-title":"The American journal of the medical sciences"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:42:59Z","timestamp":1786084979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000307"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.009","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium\u2013Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}